Pharmafile Logo
Pharmafocus logo
Advanced Search

psoriasis

Showing 15 posts of 67 posts found.

novartis_outside_1

Novartis’ Cosentyx approved in China for plaque psoriasis

April 2, 2019
Manufacturing and Production, Sales and Marketing China, Cosentyx, Novartis, pharma, psoriasis

Novartis has revealed that its interleukin-17A (IL-17A) Cosentyx (secukinumab) has been authorised for use in China in the treatment of …

News
abbvie_0

Japan awards AbbVie’s Skyrizi with first approval, in 4 psoriasis indications

March 27, 2019
Research and Development, Sales and Marketing AbbVie, Japan, Skyrizi, pharma, psoriasis

AbbVie has announced that its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab) has been awarded approval in Japan from the nation’s Ministry …

News
novartis_side_building

Novartis’ Cosentyx tops Janssen’s Stelara in moderate-to-severe psoriasis trial

March 5, 2019
Manufacturing and Production, Research and Development Cosentyx, Janssen, Novartis, Stelara, pharma, psoriasis

New data has been revealed in support of Novartis’ Cosentyx (secukinumab) in the treatment of moderate-to-severe plaque psoriasis, demonstrating the …

News
abbvie_0

AbbVie’s Skyrizi scoops up CHMP recommendation for moderate to severe plaque psoriasis

March 4, 2019
Sales and Marketing AbbVie, pharma, psoriasis

AbbVie’s interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab) has secured recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP), …

News

NICE approves Cimzia but blocks Ilumetri in treatment of psoriasis

December 4, 2018
Manufacturing and Production, Sales and Marketing Almirall, Cimzia, Ilumetri, NICE, UCB, UK, pharma, psoriasis

UK drug watchdog NICE has announced two new recommendations relating to medicines for the treatment of psoriasis, approving UCB Pharma’s …

News
janssen_latest_logo_on_sign_closer

Janssen’s Tremfya maintains skin clearance after 3 years in plaque psoriasis

October 22, 2018
Research and Development, Sales and Marketing Janssen, Tremfya, pharma, plaque psoriasis, psoriasis

Janssen has revealed new long-term data for its IL-23 inhibitor Tremfya (guselkumab) in moderate to severe plaque psoriasis, demonstrating skin …

News
celgene_1_02

Celgene’s Otezla impresses at Phase 3 in scalp psoriasis

October 9, 2018
Manufacturing and Production, Research and Development Celgene, pharma, psoriasis

Celgene has unveiled new Phase 3 data for Otezla (apremilast), its inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine …

News
almirall-605x338

Almirall’s Ilumetri scores EU approval in chronic plaque psoriasis

September 19, 2018
Research and Development, Sales and Marketing Almirall, EADV 2018, Ilumetri, pharma, psoriasis

Hot on the heels of the European Academy of Dermatology and Venereology Congress (EADV) 2018 where psoriasis took centre stage, …

News

UCB brings promising plaque psoriasis data to EADV 2018

September 14, 2018
Medical Communications, Research and Development EADV 2018, UCB, pharma, psoriasis

UCB has joined in on the wave of new psoriasis data emerging from the European Academy of Dermatology and Venereology …

News
novartis_outside_1

Novartis doubles down on Cosentyx’s efficacy in psoriasis with extensive real-world data

September 13, 2018
Research and Development Cosentyx, Novartis, pharma, psoriasis

Novartis was yet another company to reveal new data on a psoriasis drug at the European Academy of Dermatology and …

News
celgene_1_02

Celgene’s Otezla produces “meaningful benefits” beyond traditional metrics in plaque psoriasis

September 13, 2018
Research and Development Celgene, otezla, pharma, psoriasis

Celgene made its voice heard amongst the chorus of new psoriasis data emerging from the European Academy of Dermatology and …

News
janssen_latest_logo_on_sign

Phase 3 data presents strong case for switching from Humira to Janssen’s Tremfya in plaque psoriasis

September 13, 2018
Research and Development Humira, Janssen, Tremfya, pharma, psoriasis

Janssen has unveiled new Phase 3 data derived from two separate trials on the efficacy and benefits of switching to …

News

BMS’ investigational psoriasis drug hits primary endpoint in skin clearance at Phase 2

September 12, 2018
Research and Development BMS, BMS-986165, Bristol-Myers Squibb, pharma, psoriasis

Bristol-Myers Squibb has unveiled new Phase 2 data for its investigational oral, selective tyrosine kinase 2 (TYK2) inhibitor, known as …

News
valeant_web

FDA rejects Valeant plaque psoriasis lotion over pharmacokinetic concerns

June 19, 2018
Manufacturing and Production, Sales and Marketing FDA, Valeant, pharma, psoriasis

Beleaguered pharma firm Valeant has come up against another bump in the road as its plaque psoriasis lotion Duobrii (halobetasol …

News

UCB’s Cimzia secures first-of-its-kind FDA approval in plaque psoriasis

May 29, 2018
Manufacturing and Production, Sales and Marketing Cimzia, FDA, UCB, US, pharma, psoriasis

The FDA has expanded the label for UCB’s Cimzia (certolizumab pegol) in the US, approving the therapy for the treatment …

News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024